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The misconception that infertility is typically associated with the female is commonly faced in the
management of infertile men. It is uncommon for a patient to present for an infertility evaluation with an
abnormal semen analysis report before an extensive female partner workup has been performed.
Additionally, a man is usually considered fertile based only on seminal parameters without a physical exam.
This behavior may lead to a delay in both the exact diagnosis and in possible specific infertility treatment.
Moreover, male factor infertility can result from an underlying medical condition that is often treatable but
could possibly be life-threatening.
The responsibility of male factor in couple’s infertility has been exponentially rising in recent years due to a
comprehensive evaluation of reproductive male function and improved diagnostic tools. Despite this
improvement in diagnosis, azoospermia is always the most challenging topic associated with infertility
treatment. Several conditions that interfere with spermatogenesis and reduce sperm production and quality
can lead to azoospermia. Azoospermia may also occur because of a reproductive tract obstruction. Optimal
management of patients with azoospermia requires a full understanding of the disease etiology. This review
will discuss in detail the epidemiology and etiology of azoospermia. A thorough literature survey was
performed using the Medline, EMBASE, BIOSIS, and Cochrane databases. We restricted the survey to clinical
publications that were relevant to male infertility and azoospermia. Many of the recommendations included
are not based on controlled studies.
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& INTRODUCTION
The development of intracytoplasmic sperm injection
(ICSI) as an efficient therapy for severe male factor infertility
has become an appropriate treatment for the majority of
male reproductive tract deficiencies (1). Usually, even men
with potentially treatable causes of infertility are treated
with assisted reproductive techniques (ARTs) instead of
specific therapy. However, once the diagnosis of azoosper-
mia is established, no sperm can be found in the ejaculate; as
a consequence, assisted reproduction cannot be applied due
to the absence of sperm. Therefore, an understanding of
azoospermia is very important for urologists.
Azoospermia, defined as the absence of sperm in the
ejaculate, is identified in approximately 1% of all men and in
10 to 15% of infertile males (2). A precise diagnosis of
azoospermia and systematic evaluation of the patient to
establish the disease etiology are needed to guide appro-
priate management options and to determine the associated
cost benefits, risks and prognosis for treatment success.
Clinicians should also provide adequate counseling for the
couple and generous support for patients with severe male
factor infertility.
In the past, men with azoospermia were classified as
infertile, and a sperm donor was initially considered one of
the best options for conceiving. Currently, the knowledge
that many causes of azoospermia can be reversed is
widespread in the medical literature and practice. Thus,
any trusted specialized assisted reproductive center will
request a urologist/andrologist to provide sperm for an
ART procedure. As a result, the urologist, even if he/she is
not a specialist in the infertility field, is responsible for the
adequate evaluation, diagnosis and treatment of the under-
lying condition whenever possible instead of only providing
sperm extracted from the testicle or epididymis. This review
discusses the most common causes of azoospermia that
should be considered during the management of azoosper-
mic men. We also included algorithms that will help to
clarify and organize the etiologies and mechanisms of
azoospermia.
& DIAGNOSIS OF AZOOSPERMIA
Azoospermia is defined as the complete absence of sperm
from the ejaculate. This diagnosis must be confirmed by
centrifugation of a semen specimen for 15 min at room
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temperature with high-powered microscopic examination of
the pellet and a centrifugation speed of at least 3,000 g (3).
The semen analysis should be performed according to the
2010 World Health Organization guidelines, and at least two
semen samples obtained more than two weeks apart should
be examined (3,4).
The finding of even small quantities of sperm in the
centrifuged specimen excludes complete ductal obstruction
and offers the potential for immediate sperm cryopreserva-
tion for ICSI cycles. Ron-El et al. showed that it is possible to
detect sperm in 35% of the men who were thought to have
nonobstructive azoospermia when a meticulous routine
analysis of a centrifuged semen specimen was performed
(5). These findings are interesting because patients routinely
present with one or more semen analyses that were
previously performed without using standardized centrifu-
gation procedures. Urologists must always consider the
need to repeat the seminal analysis to consistently confirm
the diagnosis of azoospermia.
& EVALUATION OF AZOOSPERMIC PATIENTS
Medical history. A complete evaluation should include
a complete medical and surgical history, history of
childhood illnesses (such as viral orchitis or cry-
ptorchidism) and genital trauma, medications and
allergies, and an inspection of past infections, such as
sexually transmitted diseases (6). It is important to assess
gonadotoxin exposures and prior radiation therapy or
chemotherapy. In addition, approximately 1% of male
infertility cases may be a consequence of a serious or
potentially fatal disorder (7). Thus, it is always important to
recognize that infertility may be the initial manifestation of
a severe medical condition (8).
Physical examination. A general physical examination is
an essential part of the evaluation of an azoospermic man,
and the patient should be examined in the supine and
standing position in a warm room. A cold room causes
contraction of the dartos and makes the examination
difficult.
The presence of clinical varicocele should be investigated
and correctly classification, as some recent studies have
shown that varicocele grade is related to the prognosis of
treatment (9-12). These findings suggest that high-grade
varicocele could be more frequently related to azoospermia,
whereas varicocele grade I is not sufficient to explain the
entire disease etiology.
Appropriate sexual development must be assessed.
Androgen deficiency should be suspected in the presence
of diminished body hair distribution, gynecomastia or
eunuchoid proportions (13). During the physical examina-
tion, men who are incompletely masculinized can be
identified by excessively long extremities that occurred
due to the absence of adequate epiphyseal closure at the
time of puberty; this characteristic is observed in men with
Kallmann’s or Klinefelter’s syndrome (14). The thyroid must
be palpated, and the heart and lungs should be auscultated.
The breasts should be observed and palpated for gyneco-
mastia, which can be related to estrogen-secreting testicular
tumors or adrenal tumors. The abdomen must be cautiously
palpated. In addition to the general physical examination, a
particular focus must be given to the genitalia, as described
below.
Palpation of the testes and measurement of their size is
mandatory. Normal adult testicular measurements have
been established to be at least 4.6 cm in length and 2.6 cm in
width, resulting in a volume ranging from 18 to 20 cm3.
Because 85% of the testicular volume is associated with
sperm production, a decreased testicular size indicates
impaired spermatogenic potential (15). The testes of patients
with nonobstructive azoospermia will typically measure
less than 15 cm3 in volume, and the epididymis will be flat.
In the vast majority of patients, obstructive azoospermia
may be easily distinguished from nonobstructive azoosper-
mia through a thorough analysis of clinical diagnostic
parameters. Ninety-six percent of men with obstructive
azoospermia had follicle-stimulating hormone (FSH) levels
of 7.6 mIU/ml or less or a testicular long axis greater than
4.6 cm. Conversely, 89% of men with nonobstructive
azoospermia had FSH levels greater than 7.6 mIU/ml or a
testicular long axis of 4.6 cm or less. Based on these results,
we believe that an isolated diagnostic testicular biopsy is
rarely indicated (16).
The presence and consistency of both the vasa and
epididymides should be evaluated. Palpation can complete
the diagnosis of a bilateral congenital absence of the vas
deferens, and scrotal exploration is not needed to make the
diagnosis (Figure 1) (17).
A digital rectal exam is necessary to look for masses and
to examine the size and consistency of the prostate. Under
normal conditions, the seminal vesicles may not be palpable
but may be prominent in the setting of ejaculatory duct
obstruction.
Endocrine evaluation. An endocrinologic evaluation of
patients who have severe male factor infertility leads to
specific diagnoses and treatment strategies in a large
population of infertile men (18). Although some authors
recommend routine screening of the male hypothalamic-
pituitary-gonadal axis in all patients, endocrine screening of
men with sperm counts of less than 10 million/mL based on
serum testosterone and FSH levels alone will detect the vast
majority of clinically significant endocrinopathies (19). In
addition to cases of seminal parameter abnormalities, an
investigation of those patients presenting with impaired
sexual function or other clinical findings suggestive of
endocrinopathy, such as a marked reduction in testicular
size or gynecomastia, is recommended (20).
If the testosterone level is low, a more complete
evaluation will be necessary to analyze total and free
testosterone, luteinizing hormone (LH), prolactin and
estradiol levels. The information obtained from a complete
endocrine profile may help to elucidate the etiology (21).
Semen analysis. Azoospermic patients with a normal
ejaculate volume may have either obstruction of the
reproductive system or abnormalities in spermatogenesis.
Azoospermic men with a low semen volume and normal-
sized testes may have ejaculatory dysfunction or ejaculatory
duct obstruction. All patients presenting with absent
ejaculation or low-volume ejaculation (,1.5 ml) should be
asked to repeat the semen analysis and provide a
postejaculation urine specimen. It is important to keep in
mind that the majority of seminal fluid is contributed by the
seminal vesicle. The ejaculated volume is an essential tool in
the evaluation of an azoospermic patient, and the use of a
diagnostic algorithm may prevent mistakes (Figure 1).
Diagnostic testis biopsy. Testicular histology is the only
definitive way to diagnose azoospermia. However, the
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pattern of the testis tissue is heterogeneous, and
spermatogenesis most often occurs only in focal areas;
therefore, a biopsy is rarely used as a diagnostic tool (22).
Usually, testicular characteristics and laboratory findings
are suggestive of nonobstructive azoospermia. Thus,
testicular sperm extraction (TESE) can be performed at the
same time as ART in a specialized assisted reproduction
center, which allows for sperm cryopreservation during the
procedure and avoids a testicular biopsy.
In select patients with azoospermia, a normal testicular
size, a palpable vas deferens and normal serum FSH levels,
testis biopsies may be required to differentiate obstruction
from disorders of spermatogenesis (Figure 1) (4). A normal
testicular biopsy is pathognomonic for obstruction, and a
vasography should be indicated to identify the site of the
obstruction. Furthermore, scrotal exploration or endoscopic
intervention may be required (Figure 1).
& ETIOLOGIES OF AZOOSPERMIA
Although there are many causes of azoospermia, the
etiologies of this disorder fall into three general categories:
pretesticular, testicular and post-testicular. Pretesticular
causes of azoospermia are endocrine abnormalities that
adversely affect spermatogenesis. Testicular etiologies
involve intrinsic disorders of spermatogenesis inside the
testes. The post-testicular causes of azoospermia include
obstruction of the ductal system at any location of the male
reproductive tract. Every etiology of azoospermia is
associated with a different prognosis, ranging from returns
of production to simply finding sperm in the reproductive
tract. The pretesticular and post-testicular abnormalities
that cause azoospermia are commonly treatable, which may
facilitate the restoration of fertility potential. Conversely,
testicular disorders are generally irreversible, and the
success rates for interventions associated with intrinsic
testicular abnormalities are significantly lower. The etiolo-
gies, mechanisms and prognoses of azoospermia are
summarized in Figure 2.
Pretesticular causes
Pretesticular causes, also called secondary testicular
failure, usually result from pathological endocrine condi-
tions. Although an uncommon cause of male subfertility, up
to 3% of infertile men will have an underlying endocrino-
pathy (19).
Hypogonadotropic hypogonadism. Typical causes of
hypogonadotropic hypogonadism (HGH) include
Kallmann’s syndrome, pituitary trauma, pituitary tumors
and anabolic steroid use. HGH is a rare cause of male
infertility, and the disorder can be classified as congenital or
acquired (23).
Kallmann’s syndrome is a congenital cause of HGH and is
associated with a malformation of the midline cranial
structures (24). In this syndrome, the pathophysiology is a
defect at the level of the hypothalamic secretion of
gonadotropin-releasing hormone (GnRH) due to the failure
of the GnRH-releasing neurons to migrate to the olfactory
lobe during development. Kallman syndrome is the most
frequently reported form of congenital HGH, occurring in
between 1:10,000 and 1:60,000 births (21). Segregation
analysis in familial cases has demonstrated diverse inheri-
tance patterns, suggesting the existence of several genes that
regulate GnRH secretion. Genetic defects have been
demonstrated in the KAL gene, located in the Xp22.3
region, that explain the X-linked form of the disease (25).
Figure 1 - Algorithm for the evaluation of patients with azoospermia.
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The clinical presentation of Kallmann’s syndrome depends
on the degree of hypogonadism. Most patients undergo
delayed puberty, although those with less severe defects
may present with a normal phenotype and mild sub-
fertility. Other findings include anosmia, cleft palate and
small testes. In more severe cases, congenital deafness,
asymmetry of the cranium and the face, cerebellar dys-
function, cryptorchidism, and renal abnormalities may be
present.
Acquired causes of HGH include pituitary tumors,
pituitary trauma, panhypopituitarism and anabolic steroid
use. Exogenous testosterone inhibits the hypothalamic-
pituitary gonadal (HPG) axis and results in azoospermia
by inhibiting gonadotropins via the feedback loop of the
HPG axis, resulting in hypogonadism and infertility (18).
Excess exogenous androgens from anabolic steroid use
impair spermatogenesis by suppressing FSH levels and by
depressing intratesticular testosterone levels (26).
The initial evaluation of patients with suspected HGH
may include a pituitary MRI to rule out a pituitary tumor
(27). Pituitary tumors can cause local destruction of the
anterior pituitary. The serum prolactin level should be
measured, and hyperprolactinemia must be ruled out or
treated before initiating gonadotropin replacement therapy.
In patients with acquired HGH, normal spermatogenesis
can usually be restored by treatment with exogenous
gonadotropins or GnRH (28).
Hyperprolactinemia. Hyperprolactinemia is a form of
HGH caused by excessive prolactin secretion (6). An excess
of prolactin inhibits the hypothalamic secretion of GnRH
and has been implicated as a cause of reproductive and
sexual dysfunction. Routine screening of infertile men for
hyperprolactinemia has not been shown to be useful (29).
Prolactin has negligible physiological effects in men and is
produced in the anterior pituitary. Hyperprolactinemia
suppresses both FSH and LH and may be caused by
medications, concurrent medical illnesses, tricyclic
antidepressants, some antihypertensives, stress, or
pituitary tumors (macroadenoma or microadenoma); the
cause may also be idiopathic (30). The most common
medications that induce hyperprolactinemia are
phenothiazines, imipramine, methyldopa, and reserpine
(21). The most common causes of hyperprolactinemia
are prolactin-secreting microadenomas (,10 mm) and
prolactin-secreting macroadenomas (.10 mm) (31).
Symptoms of prolactinomas include infertility, depressed
libido, galactorrhea, headache, fatigue, and erectile
dysfunction. In patients with prolactin-secreting pituitary
adenomas, gonadotropin and testosterone levels are
commonly suppressed, whereas prolactin levels are
elevated. The level of prolactin elevation provides insight
into the type of pathology. Prolactin levels greater than
250 ng/ml, between 100 and 250 ng/ml, between 25 and
100 ng/ml, and between 0 and 25 ng/ml most commonly
correspond to macroadenoma, microadenoma, pituitary
stalk compression and normal levels, respectively (6).
Androgen resistance. Androgen resistance occurs in
approximately 1:60,000 births. More than 300 mutations
have been found in the androgen receptor gene located on
the X chromosome (Xq11-q12) (32). In addition to well-
recognized mutations localized in its 8 exons, mutations in
the gene promoter region have also been reported (33).
Because many mutations exist, the syndrome is clinically
variable and ranges from phenotypic females (complete
Figure 2 - Etiologies, mechanisms and prognoses of azoospermia.
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androgen insensitivity) to normally virilized but infertile
males (partial and minimal androgen insensitivity).
Depending on the intensity of the defect, serum
testosterone levels can be low, normal or high. It has been
reported that as many as 40% of men with low or no sperm
counts may have subtle androgen receptor abnormalities as
the primary cause (34).
Modern genetic research on the androgen receptor gene
has also led to interesting new clinical correlations with
male infertility. The androgen receptor gene has 8 exons,
and it is known that a critical region of CAG nucleotide
repeats, usually 15-30 in number, can be found in exon 1
(35). Extension of this repeat region results in spinal and
bulbar muscular atrophy (Kennedy disease), a neurodegen-
erative disease that begins around age 30; this disorder
involves muscle cramping and atrophy, including infertility
from testicular atrophy. There is now enough evidence to
propose that subtle alterations in this CAG repeat region
may also be the cause of some cases of idiopathic infertility.
Yoshida et al. recently detected longer than normal CAG
nucleotide repeats in normally virilized men with idiopathic
azoospermia (36). Furthermore, Casella et al. found that the
testicular histology in azoospermic patients is associated
with the polyglutamine length of the androgen receptor
gene (37).
Testicular etiologies. Testicular etiologies, broadly
termed as primary testicular failure, are intrinsic disorders
of spermatogenesis. Direct testicular pathology may derive
from varicocele-induced testicular damage, undescended
testes, testicular torsion, mumps orchitis, gonadotoxic
effects from medications, genetic abnormalities and
idiopathic causes. Primary testicular failure in conjunction
with azoospermia, commonly termed nonobstructive
azoospermia, is best managed by harvesting testicular
sperm for eventual ICSI. However, the exact etiology
should be determined whenever possible, and treatment
may improve the success rates of sperm retrieval.
Varicocele. Currently, there is convincing evidence in
the literature that varicoceles produce a progressive harmful
effect on the testis, and varicocelectomy has been shown to
prevent the progressive decline in testicular function and
reverse the damage (38-40). Additionally, varicocele repairs
have been documented to improve pregnancy rates and
ART outcomes (41-43). However, identifying the
individuals with varicocele who will benefit from
varicocele treatment remains a challenge for andrologists.
Azoospermia in association with a varicocele occurs in
between 5 and 10% of men (44-46). Tulloch, in 1955, was the
first to report the recovery of sperm in the ejaculate and also
subsequent pregnancy after varicocelectomy in a primarily
azoospermic patient (47). At that time, these findings
elicited renewed attention to varicocele treatment.
However, it is still unknown why varicocele can have a
devastating effect, leading to azoospermia, in some patients
while 75% of men presenting with varicocele have normal
semen findings (48,49). The large range of influence that
varicocele exerts on testicular function suggests that there is
currently no adequate diagnostic method with which to
evaluate men presenting with clinical varicocele.
Although sperm can be found in the ejaculate of
azoospermic men following varicocele repair in 21 to 55%
of cases, spontaneous pregnancies are extremely rare
(45,46,49,50). However, varicocelectomy in this population
may avoid the need for more invasive procedures, such as
TESE, by providing sperm via ejaculation for ICSI (51).
Moreover, the fertilizing ability and ICSI success rates have
been described as superior when fresh motile ejaculated
sperm are used compared with sperm provided by
testicular biopsy or microsurgical TESE (4,52).
Azoospermic patients may experience only intermittent
sperm production that results in a temporary induction of
spermatogenesis. Thus, semen cryopreservation is strongly
recommended after the initial improvement following
surgery (53).
Azoospermic men with varicocele must decide whether to
undergo varicocelectomy or microsurgical testicular sperm
extraction with ICSI. Many of these patients will ultimately
require ICSI, especially those with Sertoli cell-only patterns
or maturation arrest at the spermatocyte stage (45,49,50,54).
However, more than half of these men with maturation
arrest at the spermatid stage or hypospermatogenesis can
provide postoperative motile sperm via ejaculation (55,56).
Therefore, a testicular biopsy during varicocele repair in
azoospermic men provides histological data that can be
used as a predictor of sperm appearance in the ejaculate
after surgery and of success in sperm retrieval (45,50,57).
Additionally, this information may assist couples in decid-
ing how long to wait following varicocelectomy prior to
proceeding with ART.
The finding of a genetic etiology in infertile men with
varicocele suggests that in such patients, Yq microdeletion
screening should be performed to provide a proper
diagnosis and to avoid unnecessary procedures that will
most likely fail to improve testicular function due to a
molecular/genetic basis (58).
Undescended testes. Undescended testes are the most
common genital malformation in boys and are noted in 2.7%
of newborns and up to 0.8% of 1-year-olds (59). It is
important to differentiate cryptorchid testes from retractile
testes, a circumstance involving hyperactive cremasteric
muscles that cause the testes to periodically reside in the
inguinal canal or high scrotum. Suggested mechanisms for
cryptorchidism-induced subfertility include testicular
dysgenesis, an impaired endocrine axis, immunologic
damage, and obstruction (60). Early treatment can
potentially minimize the risk of infertility, and the success
depends on the initial position of the testicle (61). This
condition should be treated hormonally and/or surgically
before the child’s first birthday; furthermore, the parents
must be well informed about the risk, mainly because
treatment before the age of 13 years does not seem to reduce
the risk of malignancy (62).
Although the majority of men with a history of unilateral
undescended testes are capable of paternity, testicular
volume and age at orchiopexy are independent predictors
of fertility potential and sperm retrieval in men with a
history of cryptorchidism (60,63). The incidence of azoos-
permia after treatment for undescended testes is approxi-
mately 13 and 34% in unilateral and bilateral
cryptorchidism, respectively (60). However, a 30 and 80%
incidence of azoospermia results from untreated unilateral
and bilateral undescended testes, respectively (60).
Testicular torsion. Testicular torsion occurs in
approximately 1:4,000 males before the age of 25 years
(64). This disorder demands immediate surgical
exploration, and the risks of nonoperative management
are well documented (65). Testicular preservation is usually
achieved if surgical exploration is performed within 6 hours
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after the onset of symptoms. In addition to duration, other
factors, such as the degree of rotation, have been related to
testicular salvage (66,67). The most significant complication
of testicular torsion is a loss of the testis, which may lead to
impaired fertility (68). Severe oligospermia or azoospermia
is rare after unilateral testicular torsion; however, these
conditions are possible when the contralateral testis has
experienced any previous abnormality, such as orchiopexy
for an undescended testis (69).
Endocrine testicular function is expected to be normal in
the event of a lost gonad. Conversely, the exocrine testicular
function (spermatogenesis) is commonly affected (70,71).
Patients with testicular torsion seem to have bilateral
abnormalities that result in decreased spermatogenesis
(72). It is unclear whether these abnormalities are due to
an autoimmune process occurring after the rupture of the
hemato-testicular barrier, leading to the formation of
antisperm antibodies, or as a result of reperfusion-induced
injury to the testis (71,73,74). Contralateral testicular
biopsies are abnormal in up to 88% of cases at the time of
torsion; therefore, some abnormalities are believed to be
present even before the onset of torsion (68).
Mumps orchitis. Since the introduction of a vaccine
against the mumps virus, there has been a reduced risk of
mumps and its complications. On the other hand, mumps
orchitis should still be suspected in cases of scrotal swelling,
as there has been a recent increase in mumps orchitis among
pubertal and postpubertal males (75).
Pubertal mumps orchitis occurs unilaterally in 67% of
patients and bilaterally in 33% (76). Testicular atrophy
occurs in 36% of those affected bilaterally, whereas
infertility occurs in just 13% (77). However, prepubertal
mumps orchitis has little effect on future fertility (76). Thus,
it is important that urologists/andrologists are familiar with
the diagnosis, treatment and complications of this condition.
Gonadotoxins and medications. Drugs and medications
may harm male fertility through four distinct mechanisms:
1) direct gonadotoxic effects, 2) alteration of the
hypothalamic-pituitary-gonadal (HPG) axis, 3) ejaculation
dysfunction, and 4) reduction in libido. Meanwhile,
gonadotoxins affect spermatogenesis by direct injury to
germ cells in the testis or by interfering with the function
of the Sertoli cells (78). For this reason, a detailed history
of medications, including prescribed, over-the-counter,
illicit, and nutraceutical drugs, should be obtained. The
vast majority of these medications are not able to cause
azoospermia, but special attention should be given to
patients using or being administered exogenous
androgens, antiandrogens, chemotherapy agents or
radiation therapy, as well as to patients exposed to
environmental toxins, such as pesticides, fumigants,
insecticides and solvents.
Genetic. Chromosomal disorders are encountered at a
higher frequency in the infertile compared with the fertile
population (79). These chromosome alterations can
currently be diagnosed in 15% of azoospermic and 5% of
oligospermic men and represent one of the most common
genetic defects in infertile men (80,81). Therefore, it is
important that these men undergo genetic testing prior to
the use of their sperm for ART.
a- Klinefelter Syndrome. Klinefelter Syndrome (KS) is 45
times more common in men seeking infertility treatment
than in the general male population and is the most
common numerical chromosome anomaly observed in
male infertility, occurring in between 1:500 and 1:1000
males (82). KS is characterized by X chromosome polysomy,
with X disomy being the most common variant (47,XXY).
Ninety percent of men with KS have non-mosaic X
chromosome polysomes (83). Advanced maternal and
paternal age have been associated with an increased risk
of KS, and the number of sex-chromosome disomic sperm
(24,XY) in the fathers of boys with KS increases markedly as
paternal age increases (84,85).
It is well known that men with KS present with a wide
range of phenotypes and socioeconomic backgrounds, and
these differences are the main reason for delayed diagnoses.
It is estimated that only 10% of adolescents with KS are
diagnosed before puberty (86). The classical phenotype of
men with KS is characterized by tall eunuchoid body
proportions; low testosterone levels; thin facial and pubic
hair; small, hard testicles; a micropenis; sterility; and mild to
moderate cognitive deficits (87). Affected men are also
predisposed to diabetes mellitus, varicose veins, and
chronic bronchitis, and they have a higher mortality rate
due to breast cancer and non-Hodgkin lymphoma (88).
Patients are commonly azoospermic, but testicular sperm
extraction (TESE) may reveal spermatozoa in approximately
69% of KS men (89). Live births of children with normal
karyotypes have been reported (90,91). The mosaic variant is
less severe, and patients with this variant can present with
normal testicular size, complete spermatogenesis and the
presence of ejaculated sperm.
b- 47,XYY Syndrome. This syndrome is caused by
paternal nondisjunction during meiosis that results in YY
sperm, occurring in approximately 1:1000 (92). These
patients typically have a tall stature, demonstrate
decreased intelligence and exhibit antisocial behavioral
characteristics. Most men with this syndrome are
azoospermic or severely oligospermic, and testis biopsy
findings range from Sertoli cell-only to maturation arrest
patterns (93). Unlike patients with KS, serum testosterone
levels are normal in these patients.
c- XX Male Syndrome. Etiologically, 90% of these
patients present with a translocation of the SRY (testis-
determining region) from the Y to the X chromosome,
occurring in approximately 1:20,000 (94). In the other 10%,
either the translocation occurs to an autosomal
chromosome, or the individual is SRY-negative (94).
Typically, these patients have normal male external and
internal genitalia and a normal hormonal profile. Because
there is no translocation of the entire AZF region, these
patients are azoospermic and therefore not candidates for
testicular sperm extraction; these individuals should be
provided with the option of donor sperm-assisted
reproduction.
d- Mixed Gonadal Dysgenesis. Patients with mixed
gonadal dysgenesis normally have a mosaic 45,X0/46,XY
genotype and anatomically have a testis on one side and a
streak gonad on the other (92). Although this is a rare
syndrome, the normally formed testis is often cryptorchidic
and devoid of viable germ cells. The streak gonad is at risk
of developing gonadoblastoma or seminoma and should be
surgically removed (95). There are varying degrees of
ambiguity of the external genitalia.
e- Y-chromosome microdeletions. Tiepolo and Zuffardi
were the first to publish a report on six azoospermic patients
carrying deletions of the Y chromosome and postulated that
factors controlling human spermatogenesis (azoospermia
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factor; AZF) may be located on the distal portion of the
euchromatin segment of the long arm of the Y chromosome
(Yq11) (96). Twenty years later, with the development of
molecular biology technologies, the first spermatogenesis
gene was identified, and the following three distinct
intervals within the AZF region were mapped (from
proximal to distal): Yq (AZFa, AZFb and AZFc) (97,98).
Closest to the centromere, the AZFa region contains two
genes that are important in the spermatogenesis process:
DDX3Y (also known as DBY) and USP9Y (99).
Microdeletion in the AZFa region occurs in almost 1% of
men with nonobstructive azoospermia. Spermatogenic
failure is the critical clinical consequence, and to date,
there are no data in the literature to support the finding of
sperm TESE (100).
At first, the AZFb and AZFc regions seemed to be distinct
and nonoverlapping; however, the precise characterization
of the P5 to P1 interval has revealed that these regions are
actually overlapping and correspond to different sites of
ectopic homologous recombination within this region (101).
Detected in approximately 1:4000 men and found in 13%
of azoospermic and 6% of severely oligospermic men, AZFc
is the most common microdeletion region (102). An AZFc
microdeletion removes several genes that occupy this
region, with the four copies of DAZ (Deleted in
AZoospermia) being more clinically significant than with
only one copy deleted (103,104). Oates et al. have offered the
most pertinent clinical correlations to date regarding AZFc
microdeletions. In their sample of 42 men, 38% were
severely oligospermic and 62% were azoospermic. Of the
azoospermic men, 67% had some level of spermatogenesis
as detected from the testis biopsy; however, 19% of the
overall group did not have sperm available from either the
ejaculate or testis tissue (105).
As previously described, the AZFb region is not distinct
from the AZFc region but corresponds to another possible
position of ectopic homologous recombination within that
region that extends from the P5 palindrome to the P1
palindrome. The AZFb microdeletion is 6.2 Mb long,
starting in the P5 palindrome and ending in the proximal
portion of the P1 palindrome. The AZFb/AZFc microdele-
tion is longer (7.7 Mb), with its origin in P5 (as for AZFb)
and its termination at the distal end of P1 (101). The greatest
clinical meaning of these microdeletions associated is that
there is a small likelihood of sperm retrieval by TESE (100).
Combined, these two microdeletions may be found in
approximately 1 to 3% of the NOA population (106).
In a very elegant review of the literature, Foresta et al.
found that almost 5,000 infertile men had been analyzed for
the presence of Y microdeletions from 1992 to 2001. They
found that the prevalence of deletions increases with more
strict patient selection criteria. For instance, in unselected
oligozoospermic men, the prevalence is 2.9%. The preva-
lence increases to 11.6% if idiopathic oligozoospermic
patients are selected and to 14.3% if idiopathic severe
oligozoospermia patients are included. In the same manner,
unselected azoospermic patients show a deletion rate of
7.3%, but the exclusion of patients with obstructive
azoospermia causes the prevalence to rise to 10.5% and to
18% if only idiopathic forms are considered. Furthermore,
if patients are selected on the basis of their testicular
structure, the prevalence is 24.7% in cases of idiopathic
severe oligozoospermia with a testicular picture of severe
hypospermatogenesis and 34.5% in cases of idiopathic
azoospermia with a testicular histology of Sertoli cell-only
syndrome (107).
Post-testicular causes of azoospermia
Post-testicular causes of azoospermia are due to either the
obstruction of sperm delivery or ejaculatory dysfunction.
The clinical management of obstructive azoospermia
depends on its cause and also must take into account any
coexisting infertility factors in the female partner (108).
Therefore, both partners should be carefully evaluated
before making any treatment recommendations. Men pre-
senting with obstructive azoospermia may father children in
one of two ways: surgical correction of the obstruction,
which may allow the couple to conceive naturally; or
retrieval of sperm directly from the epididymis or testis,
followed by the use of ART (108). The surgical management
of obstructive azoospermia varies with the site of obstruc-
tion and depends on the presence of pathological condi-
tions, such as the absence of the vasa deferentia, vasal
obstruction and ejaculatory duct obstruction. These condi-
tions are described separately below.
Absence of the vasa deferentia. Congenital bilateral
absence of the vas deferens (CBAVD) is found in 1% of
infertile men and in up to 6% of those with obstructive
azoospermia (109). There are two possible mechanisms
responsible for this condition: 1) mutations of the cystic
fibrosis transmembrane regulator gene (CFTR) and 2)
abnormalities in the differentiation of the mesonephric
duct (110).
Cystic fibrosis (CF) is the most common autosomal
recessive disease in Caucasians, with an incidence of
1:2500 births and a carrier frequency of 1:20 (33). The
CFTR gene (7q31.2) contains 27 exons and is 250 base pairs
in length. A three-base-pair deletion in exon 10 (delta F508)
is the most common mutation found in the Caucasian
population (111), but there are more than 800 different
mutations that have been described. Another common
mutation consists of an intron 8 anomaly, called 5T (112).
Normally, seven to nine thymidines are present in this
region; a reduction to the five-thymidine variant decreases
the efficiency of the splicing of exon 9 and eventually leads
to a 10-50% reduction in CFTR mRNA (113). Eighty percent
of men with CBAVD and 43% of men with a congenital
unilateral absence of the vas deferens have detectable CFTR
gene mutations (17,113).
The clinical features of CBAVD include normal testis size
and preservation of spermatogenesis. The caput epididymis
is always present, but the corpus and the cauda are found
only occasionally. Seminal vesicles are often absent or
atrophic but may also be enlarged or cystic. The ejaculate is
acidic and low in volume [,1 ml].
Any insult to the Wolffian duct before week seven of
gestation may impair urinary and reproductive tract
formation including partial epididymal aplasia, seminal
vesicle aplasia or hypoplasia, which may lead to a low
ejaculate volume. Secondary findings include ipsilateral
renal agenesis in 11% of patients with CBAVD and in
26% of patients with unilateral vasal absence (110).
Imaging confirmation of renal agenesis is imperative
in patients with unilateral absence of the vas deferens or
in those with CBAVD lacking detectable CFTR gene
mutations.
Spermatozoa can be easily retrieved from the caput
epididymis for use in conjunction with ICSI by using either
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microsurgical or percutaneous procedures (114). If the CFTR
mutation is also present in the female, a preimplantation
diagnosis can be performed to avoid the birth of a CF
child or a CBAVD male.
Vasal obstruction. The most frequent cause of
nonpurposeful vasal obstruction is inadvertent injury
during the performance of a hernia repair. This
complication more frequently occurs when performed in
infancy but can occur after any inguinal procedure where
the vas and cord are manipulated (115). The diagnosis is
suspected when examination reveals normal testicular size
and the epididymis is full and firm. Instead of a direct vasal
injury, the postoperative inflammatory response caused by
the mesh may entrap and obstruct the inguinal vas deferens.
The exact frequency of this problem is presently unknown.
An estimated 80% of inguinal hernia operations involve the
placement of a knitted polypropylene mesh to form a
‘tension-free’ herniorrhaphy. The prosthetic mesh induces a
chronic foreign-body fibroblastic response, creating scar
tissue that imparts strength to the floor and leads to fewer
recurrences. However, little is known regarding the long-
term effects of the polypropylene mesh on the vas deferens,
especially with regard to fertility (116).
The most common cause of obstruction of the vas
deferens is vasectomy performed for elective sterilization
(117). Approximately 500,000 vasectomies are performed in
the United States each year (118). It is not surprising,
therefore, that the most common indication to perform a
vasovasostomy is to reverse a prior vasectomy to restore a
man’s fertility due to a new marriage.
Epididymal obstruction. Young’s syndrome is a triad of
disorders that encompasses chronic sinusitis, bronchiectasis
and obstructive azoospermia (119). Patients with this
syndrome have only mildly impaired respiratory function
and normal spermatogenesis. The pathophysiology of the
condition is unclear but may involve abnormal ciliary
function or abnormal mucus quality. The exact cause of
azoospermia is not completely elucidated but is most likely
due to obstruction of the epididymis by inspissated
secretions. The diagnosis is based on the occurrence of
chronic sinopulmonary infections and persistent azo-
ospermia with normal spermatogenesis, after excluding
cystic fibrosis and immotile-cilia syndrome. The sperm
appear to be normal in patients with Young’s syndrome,
and paternity has been documented in these patients (119).
Ejaculatory duct obstruction. Ejaculatory duct
obstruction is a pathological condition characterized by
the obstruction of one or both ejaculatory ducts and may be
either congenital or acquired (120,121). In 1973, Farley and
Barnes initially described ejaculatory duct obstruction,
which is responsible for 1 to 5% of male infertility cases
(122,123). Although first described in azoospermic men
showing complete blockage, it is now clear that obstruction
may manifest in several ways, including azoospermia and
oligoasthenospermia (124).
Congenital causes include extrinsic compression of the
ejaculatory ducts by Mu¨llerian (utricular) or Wolffian
(diverticular) cysts. Acquired causes may be secondary to
iatrogenic trauma (postsurgical), prostatic calcification,
seminal vesicle calculi or infected-related scar tissue.
Although there are no pathognomonic findings associated
with ejaculatory duct obstruction, quite a few clinical
findings are highly suggestive of this condition. Men with
this condition present with low-volume azoospermia;
dilated seminal vesicles; and normal secondary sex char-
acteristics, testes size, and hormonal profiles. Based on a
suspicious semen analysis results, a transrectal ultrasound
may be performed to confirm the diagnosis. Ejaculatory
duct obstruction must not be confused with an obstruction
of the vas deferens; approximately 80% of the volume of the
semen is the gel-like fluid originating from the seminal
vesicles, whereas the fraction from the testicles and
epididymis, which contain the spermatozoa, accounts for
only 5 to 10% of the volume of the semen. Thus, vasal
obstruction usually does not influence the ejaculate volume
(125).
Disorders of Ejaculation. Although this is a relatively
unusual cause of male infertility, disorders of ejaculation
present an interesting challenge to the treating physician
(126). Ejaculatory dysfunction includes a variety of
disorders with individualized treatments. Ejaculatory
dysfunction should be suspected in any patient with a low
volume (,1.0 ml) of or absent ejaculate and should be
distinguished from anorgasmia. Retrograde ejaculation can
be defined as the abnormal backward flow of semen into the
bladder with ejaculation; the etiology may be anatomic,
neurogenic, pharmacologic or idiopathic. Pharmacological
agents implicated in retrograde ejaculation include
neuroleptics, tricyclic antidepressants, alpha-blockers used
in the treatment of prostatism and certain antihypertensives
(126-128). The diagnosis of retrograde ejaculation is made by
examining the post-ejaculate urine for sperm. Although
specific criteria have not been established for a positive
post-ejaculate urinalysis, the finding of greater than 10 to 15
sperm per high-power field confirms the presence of
retrograde ejaculation. In contrast, sperm will not be
present in the urine of a patient with failure of emission,
which must be diagnosed clinically.
& EXPERT COMMENTARY
Azoospermia may be due to inadequate hormonal
stimulation, impaired spermatogenesis or an obstruction.
In the majority of cases, the assessment of both physical and
laboratory information, including semen volume, testicular
volume, the presence of bilateral vas deferens and serum
FSH level, will aid in the differentiation between the three
categories.
Seminal plasma is a potential source of biomarkers for
many disorders of the male reproductive system, including
male infertility. In the future, the identification and
characterization of different proteins expressed in the
seminal plasma of men with normal and impaired sperma-
togenesis may aid in the elucidation of the molecular basis
of male infertility and possibly azoospermia (129).
Over the past three decades, revolutionary treatments for
infertility using assisted reproductive technologies have
been developed. The first major development occurred in
1978 with the birth of baby Louise Brown, who was
conceived by in vitro fertilization. The next major develop-
ment involved gamete micromanipulation reproduction
techniques, such as intracytoplasmic sperm injection (1,130).
These highly complex technologies have been applied
with increasing frequency in the treatment of couples
around the world. Over a million children have been
conceived from assisted conception worldwide as of 2005
(131). All of these newer techniques appear to be increas-
ingly less ’natural’, and there is a dearth of information on
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these children beyond the neonatal period, especially with
regard to fertile potential. Additionally, unlike most
therapeutic procedures used in medicine, ARTs did not
undergo meticulous safety testing prior to clinical use.
There is no doubt that ICSI overcomes natural barriers
and results in the transmission of possible genetic abnorm-
alities to offspring. Infertility could be, in some way, a
natural mechanism to block the transmission of these
undesirable genetic traits to offspring. Although researchers
believe that approximately 75% or more cases of infertility
have a genetic basis, our current ability to diagnose these
defects remains limited (132). However, before the devel-
opment of ART, these men could not have reproduced by
any means.
Today, approximately 28% of azoospermic men present-
ing with genetic alterations can be diagnosed, allowing for
adequate counseling before proceeding to ART (133).
However, many patients with ‘idiopathic’ azoospermia are
thought to have a contributing but as yet unidentifiable
genetic cause. As such, there exists a risk of transmission of
these abnormalities to offspring. As urologists, we are
increasingly expected to be experts on the potential genetic
basis of azoospermia. Genetic testing and counseling should
always be considered in the management of these couples
prior to treatment to allow the couples to make an informed
decision as to whether to use the husband’s sperm.
Karyotyping and Y-chromosome microdeletion analysis
should be offered to all men with azoospermia due to
primary testicular failure prior to the use of ART with their
sperm. Because Y microdeletions are the most common
molecularly defined causes of spermatogenic failure, sig-
nificant numbers of Y-deleted boys could be expected to be
fathered through ICSI. It has been demonstrated that
spermatozoa from an oligozoospermic subject carrying a
Yq deletion are able to fertilize oocytes in vitro, suggesting
that sperm carrying a deletion possess all the characteristics
required to regulate capacitation, the acrosome reaction, and
the ability to penetrate and fertilize the oocyte (134).
Although no other health problems are associated with
microdeletion of the Y chromosome, few data exist on the
phenotypes of the sons of fathers with these genetic
abnormalities. Therefore, Y chromosome analysis should
be offered to men who have nonobstructive azoospermia or
severe oligospermia prior to performing an ICSI with their
sperm.
The simple palpation of the vas deferens could bring
attention to a wide range of lethal syndromes that include
the congenital absence of the vas deferens. If the doctor
suspects any such syndrome, genetic testing for CFTR
mutations in the female partner should be offered before
proceeding with treatments that could utilize the sperm of a
man with CBAVD. Currently, the recommendation is that if
the female partner tests positive for a CFTR mutation, the
male should be tested as well. However, if the female
partner has a negative test for CFTR mutations, testing of
the male partner is optional.
Interest has been renewed in genetic studies to determine
the underlying causes of idiopathic male infertility, but the
overwhelming trend has been to sidestep improvements in
diagnostic evaluation in favor of a more expensive, although
more efficacious, option, namely ART (18). Wherever
possible, an accurate diagnosis of the etiology of azoospermia
is important prior to the initiation of the appropriate
treatment. It is also imperative that urologists work intimately
with reproductive specialists because the timing and coordi-
nation of care may help achieve the ultimate goals, as well as
the better management of azoospermia to maximize sperm
quality, in these patients. In an ideal world, cause-specific
therapy of male-factor infertility would decrease the use of
ART, thereby avoiding the costs, risks, complications, and
treatment of the unaffected female partner.
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